Drug Discovery World

FEBRUARY 1, 2024

Regulatory agencies consider genotypic identification to be more reliable than phenotypic methods. Per regulatory guidelines, the implementation of an environmental monitoring programme is required to comply with good manufacturing practices and identification of microorganisms to species level is a minimal requirement.

Manufacturing 52

Manufacturing Genotype Gene Therapy Compliance 52

Drug Discovery World

FEBRUARY 22, 2024

Regulatory agencies consider genotypic identification to be more reliable than phenotypic methods. Per regulatory guidelines, the implementation of an environmental monitoring programme is required to comply with good manufacturing practices and identification of microorganisms to species level is a minimal requirement.

Production 52

Production Genotype Manufacturing Gene Therapy 52

Drug Discovery World

FEBRUARY 15, 2024

Regulatory agencies consider genotypic identification to be more reliable than phenotypic methods. Per regulatory guidelines, the implementation of an environmental monitoring programme is required to comply with good manufacturing practices and identification of microorganisms to species level is a minimal requirement.

Production 52

Production Genotype Manufacturing Gene Therapy 52

Drug Discovery World

FEBRUARY 8, 2024

Regulatory agencies consider genotypic identification to be more reliable than phenotypic methods. Per regulatory guidelines, the implementation of an environmental monitoring programme is required to comply with good manufacturing practices and identification of microorganisms to species level is a minimal requirement.

Manufacturing 52

Manufacturing Genotype Gene Therapy Compliance 52

Drug Discovery World

FEBRUARY 1, 2024

Regulatory agencies consider genotypic identification to be more reliable than phenotypic methods. Per regulatory guidelines, the implementation of an environmental monitoring programme is required to comply with good manufacturing practices and identification of microorganisms to species level is a minimal requirement.

Manufacturing 52

Manufacturing Genotype Gene Therapy Compliance 52

The Pharma Data

DECEMBER 9, 2020

The Chinese biopharmaceutical industry is growing in leaps and bounds, but there is still a huge unmet need when it comes to getting patients access to the breakthrough therapeutic modalities and platforms like RNAi, cell and gene therapy and others. A solution could be at hand with Overland Pharmaceuticals.

In-Vivo 52

In-Vivo In-Vitro Antibody Development 52